Form 4: Vaxart CFO Executes Tax-Related Share Withholding

Vaxart CFO Jeroen Nicolaas Grasman disposed of 31,395 shares to satisfy tax obligations related to RSU vesting.

Summary

• CFO Jeroen Nicolaas Grasman reported the disposition of 31,395 shares of Vaxart, Inc. common stock.
• The transaction occurred on May 19, 2026, at a price of $0.61 per share.
• The shares were withheld by the company to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 545,605 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a mandatory administrative tax-related transaction rather than a signal of management sentiment regarding the company's future performance.

Positives

• The transaction is a routine administrative action related to equity compensation rather than a discretionary sale.

Negatives

• The transaction represents a reduction in the direct equity stake held by the Chief Financial Officer.

Risks

• Continued reliance on equity-based compensation may lead to periodic share dilution or tax-related withholding events.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that this is a standard 'sell-to-cover' transaction common in the biotechnology sector, where executives frequently use equity grants as part of their compensation packages, necessitating tax withholding upon vesting.

Comparison to Industry Standards

• The transaction is consistent with standard corporate governance practices for executive compensation in the biotech industry.
• The use of net settlement for RSU vesting is a common mechanism to manage tax liabilities for employees.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine tax-related withholding.

Key Dates

Keywords

Vaxart, VXRT, Insider Trading, Form 4, CFO, Equity Compensation